[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 14, 1993


Author Affiliations

New England Medical Center and Tufts University School of Medicine, Boston, Mass

JAMA. 1993;270(2):216-217. doi:10.1001/jama.1993.03510020084026

The application of recent advances in protein biochemistry and molecular and cellular biology continues to dominate the field of hematology. These advances in basic and applied research have led to new understandings of disease processes, diagnostic studies, and a new generation of therapeutics. The clinical application of these new technologies has introduced novel approaches to treatment and diagnosis of many hematologic disorders.

Acute promyelocytic leukemia accounts for approximately 10% to 15% of all patients with acute leukemia. It is characterized by a unique and diagnostic cytogenetic marker involving chromosomes 15 and 17 t(15;17). The chromosome break point on chromosome 17 has been mapped to the site of the retinoic acid α-receptor.1 The retinoic acid receptor is a member of a family of steroid hormone nuclear receptors that are important in the regulation and control of normal and malignant cellular differentiation and proliferation.2 In acute promyelocytic leukemia, the cytogenetic